Prasterone Treatment for Postmenopausal Vaginal Atrophy

Clinical Guidelines and Recommendations

• The National Comprehensive Cancer Network recommends considering prasterone for women with hormone-positive breast cancer after thorough discussion of risks and benefits, particularly for aromatase inhibitor users who haven't responded to previous treatments 1
• The treatment algorithm suggests starting with non-hormonal options first, such as vaginal moisturizers and water-based lubricants, and escalating to prasterone if symptoms persist or are severe at presentation 2

Treatment Considerations for Specific Populations

• The National Comprehensive Cancer Network guidelines suggest that prasterone may be considered for women with a history of breast cancer, although limited supportive data exists for this population 1